NC
MGNX icon

nVerses Capital’s MacroGenics MGNX Stock Holding History

nVerses Capital’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$134K Buy
+29,090
New +$110K 0.21% 225

Other funds holding MGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

nVerses Capital's MGNX Position: Q2 2026 in Review

nVerses Capital opened a new position in MacroGenics (MGNX) in Q2 2026: 29,090 shares worth $134K. The stake represents 0.21% of the portfolio and ranks #225 among its holdings.

73 funds tracked by Wall St. Rank hold MGNX as of Q2 2026.

  • nVerses Capital held 29,090 shares of MacroGenics worth $134K as of Q2 2026.
  • MacroGenics was a new nVerses Capital position in Q2 2026.
  • MacroGenics made up 0.21% of nVerses Capital's portfolio in Q2 2026, its #225 holding.
  • 73 funds tracked by Wall St. Rank held MacroGenics as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.